Risk Model of Sorror et al for a Patient with Acute Myeloid Leukemia or Myelodysplasia Following Allogeneic Hematopoietic Cell Transplantation

Description

Sorror et al evaluated patients with acute myelogenous leukemia (AML) or myelodysplasia (MDS) following hematopoietic cell transplantation. They used comorbidity and disease type to identify patients who may benefit from more aggressive or novel therapy. The authors are from the Fred Hutchinson Cancer Center at the University of Washington in Seattle.

Parameters:

(1) HCT-CI (hematopoietic cell transplantation comorbidity index, see Chapter 01)

(2) hematologic risk group

Risk Group	AML	Myelodysplasia
low	first complete remission	refractory anemia (RA), RA with ringed sideroblasts
intermediate	second or higher complete remission	NA
high	refractory, relapse, transformed, secondary	RA with excess blasts, RA in transformation

Parameter	Finding	Points
HCT-CI	0 to 2	0
	>= 3	1
hematologic risk group	low	0
	intermediate	1
	high	1

total score =

= SUM(points for the 2 parameters)

Interpretation:

• minimum risk score: 0

• maximum risk score: 2

Risk Score	Overall 5 Year Survival
0	69%
1	38%
2	17%

Treatment recommendations for patients according to results:

(1) low comorbidity: candidate for prospective randomized trial of myeloablative vs nonmyeloablative conditioning

(2) high comorbidity and low risk: therapeutic decisions require additional information

(3) high comorbidity and intermediate to high risk (score 2): nonmyeloablative HCT plus novel antitumor agents

To read more or access our algorithms and calculators, please log in or register.

Description

Specialty

ICD-10